Skip to main content

Abstract

This chapter discusses the genetics, metabolic actions, substrates, inducers, and inhibitors of cytochrome P450 2C9.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kupfer A, Desmond PV, Schenker S, et al. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man [letter]. Pharmacologist. 1979;21:173.

    Google Scholar 

  2. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:12.

    Google Scholar 

  3. Sim S, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103–13.

    Article  PubMed  CAS  Google Scholar 

  4. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;61(3):174–83.

    Article  PubMed  CAS  Google Scholar 

  5. Ford N. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol. 2009;49(5):506–12.

    Article  PubMed  CAS  Google Scholar 

  6. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244–7.

    Article  PubMed  CAS  Google Scholar 

  7. Shuldiner A, O’Connell J, Bliden K, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Norgard N, Mathews K, Wall G. Drug-drug interactions between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009;43:1266–74.

    Article  PubMed  CAS  Google Scholar 

  9. Shimatani T, Inoue M, Kuroiwa T, et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: A crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther. 2006;79:144–52.

    Article  PubMed  CAS  Google Scholar 

  10. Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics. 2001;11:341–8.

    Article  PubMed  CAS  Google Scholar 

  11. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69:158–68.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Barbara Jericho MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jericho, B., Aguiar, A., Dull, R.O. (2015). CYP2C19: The Support Crew II. In: Marcucci, C., et al. A Case Approach to Perioperative Drug-Drug Interactions. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7495-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-7495-1_11

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-7494-4

  • Online ISBN: 978-1-4614-7495-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics